Daily Market Reports | 10:42 AM
An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities.
In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Australian Broker Call *Extra* Edition, featuring additional sources of research and insights on ASX-listed stocks, also enlarging the number of stocks that make up the FNArena universe.
One key difference is the *Extra* Edition will not be updated daily, but merely "regularly" depending on availability of suitable quality content. As such, the *Extra* Edition tries to build a bridge between daily updates via the Australian Broker Call Report and ad hoc news stories, that are not always timely for investors hungry for the next information update.
Investors using the *Extra* Edition as a source of input for their own share market research should thus take into account that information after publication may not be up to date, or yet awaiting another update by FNArena's team of journalists.
Similar to The Australian Broker Call Report, this *Extra* Edition includes concise but limited reviews of research recently published by Stockbrokers and other experts, which should be considered as information concerning likely market behaviour rather than advice on the securities mentioned. Do not act on the contents of this Report without first reading the important information included at the end of this Report.
The Australian Broker Call *Extra* Edition is a summary that has been prepared independently of the sources identified. Readers will check the full text of the recommendations and consult a Licenced Advisor before making any investment decision.
The copyright of this Report is owned by the publisher. Readers will not copy, forward or disseminate this Report to any other person. For more vital information about the sources included, see the bottom of this Report.
COMPANIES DISCUSSED IN THIS ISSUE
Click on a symbol for fast access.
The number next to the symbol represents the number of brokers covering it for this report -(if more than 1)
ACE BPT CU6 EDV (2) IDX IMM NHC PME PPT SKO SLC TWE
IDX INTEGRAL DIAGNOSTICS LIMITED
Medical Equipment & Devices - Overnight Price: $3.03
Jarden rates ((IDX)) as Buy (1) -
Jarden notes the ACCC has approved the proposed merger between Integral Diagnostics and Capitol Health ((CAJ)) with the divestment of one clinic in Victoria.
The scheme implementation date is December 20 when new Integral Diagnostics shares will be issued to Capitol shareholders.
Jarden downgrades the EPS forecast by -3.8% due to the change in the merger timeline.
Target price slips by -1% to $3.68. The broker maintains a Buy rating and highlights the potential earnings upside consensus has yet to account for.
This report was published on December 10, 2024.
Target price is $3.68 Current Price is $3.03 Difference: $0.65
If IDX meets the Jarden target it will return approximately 21% (excluding dividends, fees and charges).
Current consensus price target is $3.36, suggesting upside of 10.8%(ex-dividends)
The company's fiscal year ends in June.
Forecast for FY25:
Jarden forecasts a full year FY25 dividend of 6.80 cents and EPS of 10.90 cents.
At the last closing share price the estimated dividend yield is 2.24%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 27.80.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 11.0, implying annual growth of N/A.
Current consensus DPS estimate is 8.1, implying a prospective dividend yield of 2.7%.
Current consensus EPS estimate suggests the PER is 27.5.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 7.90 cents and EPS of 17.40 cents.
At the last closing share price the estimated dividend yield is 2.61%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 17.41.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 14.6, implying annual growth of 32.7%.
Current consensus DPS estimate is 10.4, implying a prospective dividend yield of 3.4%.
Current consensus EPS estimate suggests the PER is 20.8.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
IMM IMMUTEP LIMITED
Pharmaceuticals & Biotech/Lifesciences - Overnight Price: $0.36
Canaccord Genuity rates ((IMM)) as Buy (1) -
Canaccord Genuity notes Immutep's announcement of more positive data from its TACTI-003 Cohort B study was very validating, providing further color on the benefit of Efti + Keytruda combination.
The broker says the study is for the first time showing the synergistic effect of the combo drug approach, with extended median overall survival benefits and increasing number of complete responders that turn cold tumors to hot.
Buy rating and $0.95 target.
This report was published on December 12, 2024.
Target price is $0.95 Current Price is $0.36 Difference: $0.585
If IMM meets the Canaccord Genuity target it will return approximately 160% (excluding dividends, fees and charges).
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
NHC NEW HOPE CORPORATION LIMITED
Coal - Overnight Price: $5.01
Goldman Sachs rates ((NHC)) as Sell (5) -
New Hope's Q1 FY25 saleable coal production and sales were in line with Goldman Sach's estimates, with an improved performance from the Bengalla mine offsetting lower than expected volumes at New Acland due to lower coal yields.
Overall FY25 guidance was also broadly in line with the broker, resulting in minor downward revision of -3% to FY earnings, and upward revision of 2% for FY26.
The changes incorporate lower costs at Bengalla, and lower coal yields at New Acland and realised pricing going forward.
Sell rating with a $4.30 target price.
This report was published on December 11, 2024.
Target price is $4.30 Current Price is $5.01 Difference: minus $0.71 (current price is over target).
If NHC meets the Goldman Sachs target it will return approximately minus 14% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $5.38, suggesting upside of 7.3%(ex-dividends)
The company's fiscal year ends in July.
Forecast for FY25:
Goldman Sachs forecasts a full year FY25 dividend of 37.00 cents and EPS of 0.61 cents.
At the last closing share price the estimated dividend yield is 7.39%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 821.31.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 66.7, implying annual growth of 18.5%.
Current consensus DPS estimate is 39.5, implying a prospective dividend yield of 7.9%.
Current consensus EPS estimate suggests the PER is 7.5.
Forecast for FY26:
Goldman Sachs forecasts a full year FY26 dividend of 23.00 cents and EPS of 38.00 cents.
At the last closing share price the estimated dividend yield is 4.59%.
At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 13.18.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 61.8, implying annual growth of -7.3%.
Current consensus DPS estimate is 34.8, implying a prospective dividend yield of 6.9%.
Current consensus EPS estimate suggests the PER is 8.1.
Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
The full story is for FNArena subscribers only. To read the full story plus enjoy a free two-week trial to our service SIGN UP HERE
If you already had your free trial, why not join as a paying subscriber? CLICK HERE